These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37175943)

  • 1. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
    Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial non-medullary thyroid cancer: unraveling the genetic maze.
    Peiling Yang S; Ngeow J
    Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
    Hińcza K; Kowalik A; Kowalska A
    Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
    Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
    Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
    Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
    Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial non-medullary thyroid cancer: a critical review.
    Capezzone M; Robenshtok E; Cantara S; Castagna MG
    J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Hereditary Thyroid Cancer.
    Bano G; Hodgson S
    Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
    Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
    Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
    Zhang T; Xing M
    J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
    Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
    J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of
    Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
    Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
    [No Abstract]   [Full Text] [Related]  

  • 17. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic predisposition to papillary thyroid cancer.
    Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D
    Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
    Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
    BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
    Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.